• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Prometheus Biosciences Inc. (Amendment)

    2/14/22 4:35:23 PM ET
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RXDX alert in real time by email
    SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #1
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.
    Securities and Exchange Commission, Washington, D.C. 20549
    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    (Name of Issuer)
    Prometheus Biosciences, Inc.
    (Title of Class of Securities)
    Common Stock, $0.0001 Par Value Per Share

    (CUSIP Number)

    74349U108
    (Date of Event Which Requires Filing of this Statement)
    December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:
    [  ] Rule 13d-1(b)
    [ x ] Rule 13d-1(c)
    [  ] Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).



    CUSIP No. 74349U108
    (1) Names of reporting persons    Point72 Biotech Private Investments, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,848,024 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,848,024 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,848,024 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 4.7% (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     


    CUSIP No. 74349U108
    (1) Names of reporting persons    Differentiated Ventures Investments, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,848,024 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,848,024 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,848,024 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 4.7% (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     


    CUSIP No. 74349U108
    (1) Names of reporting persons    72 Investment Holdings, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,848,024 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,848,024 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,848,024 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 4.7% (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     


    CUSIP No. 74349U108
    (1) Names of reporting persons    Point72 Asset Management L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization: Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              134,537 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       134,537 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    134,537 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0.3% (see Item 4)
     
    (12) Type of reporting person (see instructions) PN
     


    CUSIP No. 74349U108
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization: Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              134,537 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       134,537 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    134,537 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0.3% (see Item 4)
     
    (12) Type of reporting person (see instructions) CO
     


    CUSIP No. 74349U108
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,982,561 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,982,561 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,982,561 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 5.1% (see Item 4)
     
    (12) Type of reporting person (see instructions) IN
     



    Item 1(a) Name of issuer:
    Prometheus Biosciences, Inc.
    Item 1(b) Address of issuer's principal executive offices:
    9410 Carroll Park Drive, San Diego, California 92121
    2(a) Name of persons filing (the “Reporting Persons”):
    This statement is filed by: (i) Point72 Biotech Private Investments, LLC (“Point72 Biotech”)
    with respect to 1,848,024 shares of the Issuer’s common stock, par value $0.0001 per
    share (“Common Stock”) of which it is the record owner; (ii) Differentiated Ventures
    Investments, LLC (“Differentiated Ventures”), the managing member of Point72 Biotech, with
    respect to the shares of Common Stock held by Point72 Biotech; (iii) 72 Investment Holdings,
    LLC (“72 Investment Holdings”), the sole member of Differentiated Ventures, with respect to
    the shares of Common Stock held by Point72 Biotech; (iv) Point72 Asset Management, L.P.
    (“Point72 Asset Management”) with respect to 134,537 shares of Common Stock held by an
    investment fund that it manages; (v) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors
    Inc.”) with respect to the shares of Common Stock held by an investment fund managed by
    Point72 Asset Management; and (vi) Steven A. Cohen (“Mr. Cohen”), the sole member of both
    72 Investment Holdings and Point72 Capital Advisors, with respect to: (A) the 1,848,024 shares
    of Common Stock beneficially owned by Point72 Biotech, Differentiated Ventures, and 72
    Investment Holdings, and (B) the 134,537 shares of Common Stock beneficially owned by
    Point72 Asset Management and Point72 Capital Advisors.
    2(b) Address or principal business office or, if none, residence:
    The address of the principal business office of the Reporting Persons is:
    72 Cummings Point Road
    Stamford, CT 06902.
    2(c) Citizenship:
    Each of Point72 Biotech, Differentiated Investors, 72 Investment Holdings, Point72 Asset
    Management and Point72 Capital Advisors is a Delaware limited liability company.
    Mr. Cohen is a United States citizen.
    2(d) Title of class of securities:
    Common Stock, $0.0001 par value per share (the “Common Stock”)
    2(e) CUSIP Number:
    74349U108

    Item 3.

    Not applicable

    Item 4. Ownership

    As of the close of business on December 31, 2021:

    1. Point72 Biotech
    (a) Amount beneficially owned: 1,848,024
    (b) Percent of class: 4.7% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 1,848,024 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 1,848,024

    2. Differentiated Ventures
    (a) Amount beneficially owned: 1,848,024
    (b) Percent of class: 4.7% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 1,848,024 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 1,848,024

    3. 72 Investment Holdings
    (a) Amount beneficially owned: 1,848,024
    (b) Percent of class: 4.7% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 1,848,024 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 1,848,024

    4. Point72 Asset Management
    (a) Amount beneficially owned: 134,537
    (b) Percent of class: 0.3% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 134,537 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 134,537

    5. Point72 Capital Advisors
    (a) Amount beneficially owned: 134,537
    (b) Percent of class: 0.3% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 134,537 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 134,537

    6. Steven A. Cohen
    (a) Amount beneficially owned: 1,982,561
    (b) Percent of class: 5.1% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 1,982,561 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 1,982,561

    Point72 Biotech is the record owner of 1,848,024 shares of Common Stock.  Differentiated
    Ventures is the managing member of Point72 Biotech and may be deemed to share beneficial
    ownership over the shares of Common Stock held by Point72 Biotech.  72 Investment Holdings
    is the sole member of Differentiated Ventures and may be deemed to share beneficial ownership
    of the shares of Common Stock of which Differentiated Ventures may be deemed the beneficial
    owner.

    Point72 Asset Management is the manager to a private investment fund that is the record owner
    of 134,537 shares of Common Stock.  Pursuant to an investment management agreement,
    Point72 Asset Management maintains investment and voting power with respect to securities
    held by such private investment fund and, as a result, may be deemed to share beneficial
    ownership over the 134,537 shares of Common Stock held by such fund.  Point72 Capital
    Advisors is the general partner of Point72 Asset Management and may be deemed to share
    beneficial ownership of the shares of Common Stock of which Point72 Asset Management may
    be deemed the beneficial owner.

    Mr. Cohen is the sole member of both 72 Investment Holdings and Point72 Capital Advisors and
    may be deemed to beneficially own both the 1,848,024 shares of Common Stock of which 72
    Investment Holdings may be deemed the beneficial owner and the 134,537 shares of Common
    Stock of which Point72 Capital Advisors may be deemed the beneficial owner.

    Each of Point72 Biotech, Differentiated Ventures, 72 Investment Holdings, Point72 Asset
    Management, Point72 Capital Advisors and Mr. Cohen disclaims beneficial ownership of any of
    the securities covered by this statement.

    Item 5. Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has
    ceased to be the beneficial owner of more than 5 percent of the class of securities, check the
    following [ ].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being
    Reporting on by the Parent Holding Company or Control Person.

    Not applicable

    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to
    above were not acquired and are not held for the purpose of or with the effect of changing or
    influencing the control of the issuer of the securities and were not acquired and are not held in
    connection with or as a participant in any transaction having that purpose or effect, other than
    activities solely in connection with a nomination under§ 240.14a-11.

    Signature.  After reasonable inquiry and to the best of my knowledge and belief, I certify that the
    information set forth in this statement is true, complete and correct.

    Dated: February 14, 2022

    POINT72 BIOTECH PRIVATE INVESTMENTS, LLC

    By: /s/ Vincent Tortorella
    Name: Vincent Tortorella
    Title: Authorized Person


    DIFFERENTIATED VENTURES INVESTMENTS, LLC

    By: /s/ Vincent Tortorella
    Name: Vincent Tortorella
    Title: Authorized Person


    72 INVESTMENT HOLDINGS, LLC

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 ASSET MANAGEMENT, L.P.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 CAPITAL ADVISORS, INC.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    STEVEN A. COHEN

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person
    Get the next $RXDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RXDX

    DatePrice TargetRatingAnalyst
    5/10/2023$160.00 → $200.00Buy → Hold
    Jefferies
    7/20/2022$51.00Buy
    Goldman
    6/10/2022$53.00Overweight
    Piper Sandler
    3/10/2022$50.00 → $52.00Outperform
    Credit Suisse
    3/10/2022$42.00 → $53.00Overweight
    Wells Fargo
    3/10/2022$47.00 → $55.00Outperform
    SVB Leerink
    2/11/2022$62.00Buy
    BTIG
    12/13/2021$46.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $RXDX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Prometheus Biosciences Inc.

      15-12G - Prometheus Biosciences, Inc. (0001718852) (Filer)

      6/27/23 3:06:42 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Prometheus Biosciences Inc.

      25-NSE - Prometheus Biosciences, Inc. (0001718852) (Subject)

      6/16/23 9:13:06 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Prometheus Biosciences Inc.

      S-8 POS - Prometheus Biosciences, Inc. (0001718852) (Filer)

      6/16/23 9:12:56 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Mckenna Mark C.

      4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)

      6/16/23 4:00:25 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Stenhouse Mark

      4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)

      6/16/23 4:00:32 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Hendrix Martin

      4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)

      6/16/23 4:00:40 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Prometheus Biosciences downgraded by Jefferies with a new price target

      Jefferies downgraded Prometheus Biosciences from Buy to Hold and set a new price target of $200.00 from $160.00 previously

      5/10/23 6:31:59 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Prometheus Biosciences with a new price target

      Goldman initiated coverage of Prometheus Biosciences with a rating of Buy and set a new price target of $51.00

      7/20/22 7:36:43 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Prometheus Biosciences with a new price target

      Piper Sandler initiated coverage of Prometheus Biosciences with a rating of Overweight and set a new price target of $53.00

      6/10/22 7:19:39 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Financials

    Live finance-specific insights

    See more
    • Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb

      – ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p<0.0001) – – ARTEMIS-UC Cohort 1 met all ranked secondary endpoints – – APOLLO-CD trial showed 26.0% endoscopic response and 49.1% clinical remission rates (p=0.002 and p<0.001, respectively, compared to prespecified historical placebo rates) – – PRA023 demonstrated favorable safety and tolerability results across both studies with no safety signal identified – – ARTEMIS-UC Cohort 1 interim analysis suggests a trend towards increased PRA023 response in CDx+ patients over all comers – – PRA023 showed a significant impact on multiple m

      12/7/22 7:00:00 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

      Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity Discussion of Phase 1 results and rationale around SSc-ILD as new PRA023 indication to be presented in conference call scheduled today at 8:00 AM EST SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today reported positive topline results fro

      12/7/21 7:00:00 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Prometheus Biosciences Inc. (Amendment)

      SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)

      3/8/23 5:02:07 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Prometheus Biosciences Inc. (Amendment)

      SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)

      2/14/23 4:27:18 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Prometheus Biosciences Inc. (Amendment)

      SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)

      2/14/23 3:01:42 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Leadership Updates

    Live Leadership Updates

    See more

    $RXDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cellino Appoints Chris Gibson to Board of Directors

      Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024933617/en/Chris Gibson, Ph.D., Co-Founder & CEO, Recursion. (Photo credit: Recursion) Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven drug discovery. Dr. Gibson has led a number of key partnerships for Recursion with leading pharma and tech companies, including Roche/Genente

      10/24/24 8:00:00 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress

      - Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn's disease (CD) - - Phase 1a trial results of PRA023 in normal healthy volunteers expected in fourth quarter 2021 - - Strong cash position of $304 million as of June 30, 2021 - SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bo

      8/11/21 4:01:00 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psychedelic Science Leader Eleusis Announces Four New Board Appointments, Further Strengthening Leadership

      Eleusis, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced the appointment of four highly experienced business leaders to its board of directors. The new directors' deep expertise building high-growth, high-impact life science companies complements Eleusis's world-class leadership team. The appointees include: David Socks, former CEO of Phathom Pharmaceuticals, joining as Chair of the board Robert Hershberg, M.D., Ph.D., former CBO and CSO of Celgene John Tucker, CEO of SC Pharmaceuticals Esther van den Boom, Managing Partner at van den Boom & Associates "We are delighted to welcome these four exceptional d

      7/12/21 8:00:00 AM ET
      $RXDX
      $PASG
      $PHAT
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Cellino Appoints Chris Gibson to Board of Directors

      Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024933617/en/Chris Gibson, Ph.D., Co-Founder & CEO, Recursion. (Photo credit: Recursion) Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven drug discovery. Dr. Gibson has led a number of key partnerships for Recursion with leading pharma and tech companies, including Roche/Genente

      10/24/24 8:00:00 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck Completes Acquisition of Prometheus Biosciences, Inc.

      Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn's disease and other autoimmune conditions Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. ("Prometheus") (NASDAQ:RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. "The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This transaction is anoth

      6/16/23 4:04:00 PM ET
      $MRK
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

      SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today reported financial results for the quarter ended March 31, 2023. Prometheus to be Acquired by Merck On April 15, 2023, Merck and Prometheus Biosciences entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion. The transaction is expected to close in the th

      5/9/23 4:00:00 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care